论文部分内容阅读
目的:观察并探讨真武汤(加减)联合奥曲肽治疗肝硬化顽固性腹水的临床治疗效果。方法:此次研究开展于2016年1月—2016年8月,选取我院收治的肝硬化顽固性腹水患者60例,将其分为常规组(n=30)与研究组(n=30)。常规组患者应用常规护肝、止血、扩容药物联合奥曲肽治疗,研究组在常规组治疗基础上服用真武汤,对比研究组与常规组的治疗效果。结果:研究组取得96.6%的治疗总有效率,常规组取得76.6%的治疗总有效率,组间比较差异具有统计学意义(P<0.05);研究组出现3.33%的不良反应率,常规组出现23.3%的不良反应率,组间比较差异具有统计学意义(P<0.05)。讨论:对肝硬化顽固性腹水患者采用真武汤(加减)联合奥曲肽治疗,临床疗效显著,不良反应较小,具有临床推广价值,适合临床应用。
Objective: To observe and discuss Zhenwu decoction combined with octreotide in the treatment of refractory ascites due to cirrhosis. Methods: From January 2016 to August 2016, 60 patients with cirrhosis and refractory ascites admitted to our hospital were divided into two groups: normotensive group (n = 30) and study group (n = 30) . Conventional patients with conventional liver protection, bleeding, dilatation of drugs combined with octreotide treatment, the study group in the conventional treatment group taking Zhenwu Tang, the control group and the conventional treatment group. Results: The total effective rate was 96.6% in the study group and 76.6% in the conventional group, the difference was statistically significant (P <0.05). The adverse reaction rate of the study group was 3.33% There was a 23.3% adverse reaction rate, the difference between the groups was statistically significant (P <0.05). Discussion: The treatment of patients with cirrhosis and refractory ascites Zhenwu Tang (plus and minus) combined with octreotide treatment, significant clinical effect, minor adverse reactions, with clinical value of promotion, suitable for clinical applications.